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Receptor structure-based discovery of
non-metabolite agonists for the succinate
receptor GPR91
Mette Trauelsen 1, Elisabeth Rexen Ulven 3, Siv A. Hjorth 2, Matjaz Brvar 3, Claudia Monaco 4,
Thomas M. Frimurer 1,*, Thue W. Schwartz 1,2,*
ABSTRACT
Objective: Besides functioning as an intracellular metabolite, succinate acts as a stress-induced extracellular signal through activation of GPR91
(SUCNR1) for which we lack suitable pharmacological tools.
Methods and results: Here we ﬁrst determined that the cis conformation of the succinate backbone is preferred and that certain backbone
modiﬁcations are allowed for GPR91 activation. Through receptor modeling over the X-ray structure of the closely related P2Y1 receptor, we
discovered that the binding pocket is partly occupied by a segment of an extracellular loop and that succinate therefore binds in a very different mode
than generally believed. Importantly, an empty side-pocket is identiﬁed next to the succinate binding site. All this information formed the basis for a
substructure-based search query, which, combined with molecular docking, was used in virtual screening of the ZINC database to pick two serial
mini-libraries of a total of only 245 compounds from which sub-micromolar, selective GPR91 agonists of unique structures were identiﬁed. The best
compounds were backbone-modiﬁed succinate analogs in which an amide-linked hydrophobic moiety docked into the side-pocket next to succinate
as shown by both loss- and gain-of-function mutagenesis. These compounds displayed GPR91-dependent activity in altering cytokine expression in
human M2 macrophages similar to succinate, and importantly were devoid of any effect on the major intracellular target, succinate dehydrogenase.
Conclusions: These novel, synthetic non-metabolite GPR91 agonists will be valuable both as pharmacological tools to delineate the GPR91-
mediated functions of succinate and as leads for the development of GPR91-targeted drugs to potentially treat low grade metabolic inﬂam-
mation and diabetic complications such as retinopathy and nephropathy.
 2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. INTRODUCTION
It is becoming increasingly clear that key metabolites function not only as
energy sources and building blocks but can act also as extracellular
messengers signaling through G protein coupled receptors (GPCRs)
similarly to hormones and neurotransmitters [1]. Succinate, which has
for many years solely has been viewed as a TCA cycle intermediate, is
one of these signaling metabolites. Already in 2004, succinate was
shown to be the ligand for the G-protein coupled receptor (GPCR) GPR91
[2]. The receptor was predominantly found to be expressed in the kidney,
spleen, liver, and small intestine [2]. In the following years most attention
was paid to the pro-hypertensive effect of GPR91 associated with renin-
release [3]. In the liver, stress-induced succinate accumulation and
GPR91 activation has been linked to development of ﬁbrosis due to its
expression in hepatic stellate cells, which, upon succinate stimulation,
produces ﬁbrogenic factors in a GPR91-dependent manner [4,5].
During normal physiological conditions, plasma levels of succinate
range between 2 and 30 mM for humans and 6e17 mM for rodents
[5e8]. These levels are below the reported EC50 values for GPR91
activation [1]; however, metabolic stress conditions such as hyper-
glycemia and hypoxia cause the levels of succinate to rise both locally
and in the circulation, enabling activation of GPR91 [5,7,9e11].
Notably, several of the classical rodent models of metabolic dysfunc-
tion have all displayed elevated plasma levels of succinate [7], a ﬁnding
also established in patients suffering from Type 2 diabetes (T2D) [12].
GPR91 has been proposed to be involved in the development of dia-
betes complications including neuronal VEGF-mediated neo-
vascularization in diabetic retinopathy [3,13,14] as well as in diabetic
nephropathy [9,15]. Adipocytes also express GPR91 and activation of
the receptor inhibits lipolysis [16]. The physiological role of GPR91 on
whole body metabolism, however, is still unclear as GPR91 deﬁciency
in mice challenged with HFD has been reported both to give impaired
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[17] and improved glucose tolerance [12]. McCreath and colleagues
also observed dramatic changes in WAT composition [17], something
that also was not conﬁrmed by van Diepen et al., who notably proposed
that a dramatic decrease in inﬁltrating macrophages was the main
driver of the improved glucose tolerance in GPR91 deﬁcient mice [12].
In fact, GPR91 does seem to be an important regulator of innate im-
munity, particularly as an activator of dendritic cells [18] and macro-
phages [19].
Importantly, independent of GPR91 signaling, succinate can cause a
number of intracellular responses, including post translational modi-
ﬁcations [20], HIF-1a stabilization [21], production of mitochondrial
reactive oxygen species (ROS) [11], and overall changes to cellular
metabolism owing to its central role in the TCA cycle. Due to such non-
receptor mediated effects, the endogenous metabolite succinate as
such is not a reliable agent to delineate the speciﬁc physiological
importance of GPR91. The aim of the present study, therefore, was to
develop drug-like non-metabolite GPR91 agonists as potential phar-
macological tools by use of a receptor structure-based approach.
2. MATERIALS AND METHODS
2.1. Compound acquisition and preparation
Ligands for library 1 and 2 were purchased from a range of vendors
including Enamines, Vitas-M Laboratories, ChemDIv, Interbioscreen,
and Key Organics. Succinate and other small carboxylic acids for
Figure 1 were purchased from SigmaeAldrich and Akos.
All purchased compounds were spun down and subsequently dissolved
in 100% dimethyl sulfoxide (DMSO) to achieve a ﬁnal concentration of
50 mM and left to shake overnight. Dilution rows of the 50 mM stock
solutions were subsequently prepared to obtain concentrations suitable
for cell-based assays. It is important to mention that all presented
structures were conﬁrmed using proton (1H) NMR spectra at 300/
400 MHz and liquid chromatographymass spectrometry (LC-MS)
analysis conﬁrmed a minimum purity of 95% for all compounds.
2.2. Synthesis of enantiomerically pure compounds
All enantiomerically pure compounds were synthesized by the same
general route. D- or L-aspartate protected as the corresponding
dimethyl esters were coupled with the appropriate carboxylic acid
building block using ﬂuoro-N, N, N0, N0-bis(tetramethylene)for-
mamidinium hexaﬂuorophosphate [22]. Lithium hydroxide-promoted
ester hydrolysis gave the desired test compounds. The acid building
blocks were either commercially available (compound 184), or syn-
thesized by Williamson ether synthesis (compound 131) or by Suzuki
cross coupling using Buchwald’s fourth generation XPhos precatalyst
[23] (compound 130), both followed by ester hydrolysis. Detailed
procedures and compound characterization can be found in the
Supplementary information.
Figure 1: GPR91 activation properties of TCA cycle metabolites and synthetic succinate analogs. A) The main metabolites of the TCA cycle are depicted with structures.
Compounds that are able to activate GPR91 are indicated in green and inactive compounds are in gray. B) Dose response curves for the ‘active’ succinate analogs measured as
induction of IP3 turnover in GPR91 transfected HEK-293 cells (N¼ 3); L-aspartate and D-malate are included as representatives of the inactive compounds. Symbols used for each
compound are annotated in panels C and D. C) Chemical structures of all compounds that were found to be able to activate GPR91. D) Chemical structures of compounds unable to
activate GPR91. All compounds are named after their appearance at physiological pH; succinate instead of succinic acid, malate instead of malic acid etc. However, for esthetic
reasons all compound structures are shown in their neutral form.
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2.3. Homology modeling and molecular docking
Homology models of the human (UniProtID: Q9BXA5) and mouse
(UniProtID: Q99MT6) GPR91 receptor was constructed using ICM 3.8
(Molsoft L.L.C. 11199 Sorrento Valley Road, S209 San Diego CA
92121) and the human P2Y1 receptor in complex with MRS2500
(pdbid: 4XNW) as a template (36% sequence identity, alignment shown
in Figure S1). The models were relaxed using 300 steps of Cartesian
minimization, followed by a global side-chain minimization (300
moves).
The initial homology models were further reﬁned using Rosetta version
3.4 and subjected to 1,000 steps of full-atom structure relaxation using
the membrane force ﬁeld [24] using default parameters. The best
scored model was converted into an ICM object and expanded by 21
models using elastic network modeling employing the ICM 3.8e5
(Molsoft L.L.C. 11199 Sorrento Valley Road, S209 San Diego CA 92121)
to broadly sample the binding pocket geometry and the conformational
variability of the receptor. 3D grid maps that represent the van der
Waals, electrostatics, hydrophobic and hydrogen bonding potentials of
the selected binding pocket residues were calculated using a grid
spacing of 0.5 A and a margin of 4 A (default values) were generated
sequentially for all receptor conformations in the stack. Against each of
these models, we computationally docked succinate and the com-
pounds in library 1 and 2 using the four-dimensional docking protocol
(4D Docking) in ICM (using default parameter setting) [25]. The “docking
effort” parameter controlling the number of Monte Carlo steps were set
to 3. In brief, the scoring function uses steric, entropic, hydrogen
bonding, hydrophobic and electrostatic terms to calculate the score and
also includes a correction term proportional to the number of atoms in
the ligand to avoid bias towards larger ligands [25].
2.4. Structure-based virtual screening of compounds
The In-Stock subset of ZINC (http://zinc.docking.org) containing
12,782,590 biologically relevant screening molecules stripped for
counter ions and assigned stereomers, tautomers, protonation states,
and charges were stored in fast search index ﬁles using Babel [26].
2.4.1. Library 1
A Markush substructure which included i) a carboxylic acid and/or
acidic (bio)isostere ii) one e three atom linker to an acceptor and/or
another carboxylic acid/acidic (bio)isoster and iii) up to three R groups
connected to the linker atoms was used as a query to search the ZINC
database. Several classes of accepted molecules were rejected based
on the following criteria: compounds with long alkyl chains and many
rotatable bonds, as well as compounds with high molecular weight
(>450) and clogP (>5) were deprioritized. Accepted compounds were
prioritized based on their predicted drug-like properties (0.2 < drug-
likeness score < 1.2) using the chemo-informatics tools in ICM 3.8
(Molsoft L.L.C. 11199 Sorrento Valley Road, S209 San Diego CA
92121). Compounds were furthermore prioritized between the com-
mercial vendors based on their reliability and cost. Compounds that
were structurally different from the succinate analogs (Figure 1) were
preferentially chosen to maximize the number of different chemo-
types. The remaining compounds were subsequent clustered using
a Tc threshold ¼ 0.3 and docked to the GPR91 model. A total of 111
compounds (Table S2) were purchased from two vendors based on
manual assessment to recapitulate chemical complementary and key
interactions of the GPR91-succinate model.
2.4.2. Library 2
The identiﬁed agonists 104 and 109 were used as seed structures for
similarity-based searches of ZINC using FP2 ﬁngerprints and a cut-off
Tanimoto Coefﬁcient threshold, TC > 0.60. A total of 134 compounds
(Table S3) were purchased from four vendors using the ﬁlter criteria
above combined with SAR knowledge and predicted binding con-
formations of active library 1 compounds, which is a common
accepted practice for cherry-picking compounds for experimental
testing.
2.5. Molecular biology, cell culture, and transfection
The mGPR91 and hGPR91 receptor constructs were obtained from
Origene and cloned into the eukaryotic expression vector pCMV-Tag
(2B) (Stratagene). Point mutations were introduced by PCR using the
QuickChange method. All PCR reactions were performed using Pfu
polymerase (Stratagene) according to manufacturer’s instructions.
DNA was puriﬁed from transformed cells carrying one speciﬁc point
mutation with midi prep kit from Qiagen. All constructs were veriﬁed by
DNA sequence analysis by GATC Biotech (GATC) (Constance,
Germany).
HEK-293 cells were grown in Dulbecco’s modiﬁed Eagle’s medium
1885 (DMEM) supplemented with 10% fetal calf serum, 100 units/ml
penicillin, and 100 mg/ml streptomycin. HEK-293 cells were transiently
transfected with Lipofectamine-2000 according to manufacturer’s
protocol and supplemented with fresh medium after 5 h.
2.6. IP3 turnover assay
HEK-293 cells were plated in poly-D-lysine-coated 96-well plates
(35.000 cells/well). The following day, cells were transfected in 100 ml
transfection medium/well for a total of 5 h and thereafter incubated
with 0.5 mCi/ml myo [3H]inositol (Perkin Elmer) in 100 ml growth
medium O/N. The subsequent day cells were washed twice with
200 ml/well HBSS (Gibco, Life Technologies) and pre-incubated for
30 min at 37 C with 100 ml buffer supplemented with 10 mM LiCl.
Ligand addition was followed by 120 min incubation at 37 C. Cells
were lysed with 50 ml 10 mM formic acid followed by incubation on ice
for 30 min, 20 ml of the extract was transferred to a white 96-well plate
and 80 ml of 1:8 diluted YSi SPA scintillation beads (Perkin Elmer) was
added. After vigorous shaking, the plate was centrifuged for 5 min at
1500 rpm, and light emission (scintillation) was recorded on a Packard
Top Count NXT counter after an 8 h delay. Determinations were made
in triplicates.
2.7. Ca2þ mobilization assay
40.000 HEK-293 cells/well were plated in poly-D-lysine-coated black,
clear bottom 96-well plates (Corning). The following day, the cells
were transfected with either mGPR91, hGPR91, or empty vector
control for 5 h in 100 ml transfection medium/well and thereafter
supplemented with full medium O/N. The following day cells were
incubated at 37 C in 50 ml loading buffer/well (wash buffer: HBSS
(Gibco, Life Technologies) supplemented with 1 mM CaCl2, 1 mM
MgCl2, 2.5 mM Probenicid supplemented with 0.2% Fluo-4). After
1 h cells were washed twice with wash buffer and 100 ml wash buffer
was added/well for the assay. Cells and compounds were transferred
to the Flexstation 3 (Molecular devices, USA) and Fluo-4 ﬂuorescent
signals (relative ﬂuorescence unit, RFU) were recorded. Settings: 90 ml
height, 76 measurings, injection rate, injection vol. 25 ml. Data were
baseline corrected and presented as dose-response curves of Max RFU
e Min. RFU.
2.8. SDH assay
Succinate dehydrogenase activity was measured by a colorimetric
assay kit from Biovision (Cat# K660-100) and performed according to
manufacturer’s instructions. In brief, 6 million HEK-293 cells/well were
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harvested and washed in 1 ml PBS. The cells were then centrifuged
and resuspended in 600 ml SDH buffer and centrifuged again for
10 min, 4 C. Supernatant was transferred to a new eppendorf tube
and kept on ice. Supernatant was added to a 96 well plate, and
compounds and inhibitors were added to each well and pre-incubated
for 5 min. Standard and positive controls were then loaded and re-
action mix added to each well. Absorbance was measured at 595 nm
and activity calculated as advised by the manufacturer.
2.9. Macrophage isolation, culture and stimulation
Human monocytes were separated and puriﬁed by centrifugal elutria-
tion. Brieﬂy, human PBMCs were obtained by density centrifugation
through Ficoll of a single-donor platelet depleted residue (North London
Blood Transfusion Service, Colindale, UK). The resulting PBMCs were
centrifugally elutriated in 1% heat-inactivated FBS in RPMI in a Beckman
JE6 elutriator (Beckman, High Wycombe, UK). Monocytes separated by
this method were assessed for purity by ﬂow cytometry (FACSCan,
Becton Dickinson, Oxford, UK) and were greater than 80%. The puriﬁed
monocytes were stimulated with MCSF (100 ng/ml) in 10 cm dishes in
RPMI þ 10% FCS at a density of 1  106 cells/ml for 5 days at 37 C
(5% CO2). On day 5 the MCSF differentiated cells were lifted, counted,
and re-stimulated for 24 h with IL-4þ IL-13 (20 ng/ml) in 24 well plates
at a density of 1 106 cells/ml at 37 C, 5% CO2. On day 6, the medium
was removed and cells were stimulated with either DMSO (ﬁnal conc.
0.1%), succinate (100 mM and 500 mM), or compound 131 (10 mM and
100 mM). Cells were harvested after 2 h and 24 h incubation at 37 C
(5% CO2), washed twice with PBS, snap frozen in liquid nitrogen, and
stored at 80 C until RNA extraction was performed.
2.10. RNA extraction and gene expression
RNA from 1 mio. macrophages/condition was extracted using the
Nucleospin RNA kit (MachereyeNagel) according to manufacturer’s
instructions. In brief, cells were lysed with Buffer RA1 and b-mer-
captoethanol for 2 min in a TissueLyser LT (Qiagen). Samples were
ﬁltered on NucleoSpin Filter columns, and RNA was captured on
NucleoSpin RNA columns. Samples were DNase treated for 15 min and
eluted in 40 ml RNase free H2O. RNA concentration and quality was
measured on NanoDrop 2000 (Thermo Scientiﬁc).
cDNA was made using the Invitrogen SuperScript III First-Strand
synthesis system for RT-PCR according to manufacturer’s in-
structions. In brief, RNA concentrations were adjusted to equal values
and two consecutive RT reactions were made. RT1 mastermix con-
sisting of 5 FS buffer, random primers, and 0.1M DTT was added to
each concentration-adjusted RNA sample. Samples were heated to
70 C for 3 min. RT2 was then performed by adding mastermix
(dNTPs, RNaseOUT, Superscript III) to each sample and running a PCR
program of 5 min at 25 C, 60 min at 50 C, and 15 min at 70 C.
cDNA was stored at 20 C.
qPCR was performed in duplicates in 384 well plates; cDNA was
diluted 20-fold and mixed with PrecisionPLUS MasterMix premixed
with SYBRgreen (Primerdesign). All samples were run on a Light-
cycler 480 II (Roche) using the program: 1 cycle of 2 min 95 C, 45
cycles of 15 s 95 C, 1 min 60 C. CT values were calculated by the
2nd derivatives method and expression was evaluated by the DDCT
method [27], normalizing expression to GAPDH expression. Data are
presented as fold change and primer sequences can be found in the
Supplementary section Figure S2.
2.11. Statistical analysis
Data are presented as mean  standard error of the mean (SEM) of
absolute values, % changes or fold changes as indicated in the ﬁgures.
Data were analyzed using a one-way ANOVA multiple comparisons test
(GraphPad Prism). Statistical tests used are mentioned in the ﬁgure
legends. Values were regarded as signiﬁcant when P < 0.05.
3. RESULTS
3.1. Structure-activity relationship (SAR) for succinate activation of
GPR91
To obtain information about the SAR for succinate binding and acti-
vation of GPR91, we tested a small library of 18 succinate analogs
including other TCA cycle metabolites in transiently transfected
HEK293 cells overexpressing human GPR91 plus the modiﬁed, pro-
miscuous G protein Gqi4myr. Gqi4myr allows the otherwise presum-
ably Gi coupled GPR91 to give a robust signal through Gq measuring in
this case IP3 accumulation (Figure S3) [28]. In this assay, succinate
activated hGPR91 in a dose-dependent manner (EC50 ¼ 17 mM)
(Figure 1B). Interestingly, three of the other TCA cycle metabolites
could also activate GPR91 albeit with lower potencies than succinate:
oxaloacetate (EC50 ¼ 171 mM), L-malate (EC50 ¼ 207 mM) and a-
ketoglutarate (EC50¼ 7.3 mM) (Figure 1B). As shown in Figure 1B and
c, we also found four other dicarboxylic acid metabolites to be agonists
for GPR91 with maleate (a known GPR91 agonist) being equally potent
(EC50¼ 13 mM) and almost equally efﬁcacious as succinate, whereas
itaconate and malonate both had potencies around 1 mM (Figure 1B).
Although the physiological importance of these non-succinate me-
tabolites as ligands for GPR91 is doubtful, the fact that the metabolites
shown in Figure 1C are agonists for GPR91, in contrast to a number of
other very similar metabolites and synthetic compounds shown in
Figure 1D, provides important information about the structural re-
quirements for binding and activation of this receptor by small dicar-
boxylic acid compounds. For example, the high potency and efﬁcacy of
maleate, in contrast to the stereoisomer fumarate, indicates that the
cis backbone conformation is optimal (Figure 1). Similarly, it is clear
that certain, but not other, modiﬁcations of the succinate backbone are
allowed, for example -OH versus -NH2 (L-malate versus L-aspartate)
and that the stereochemistry of the backbone substitution has to be in
the L-conﬁguration (L-malate versus D-malate).
No IP3 response was observed with any of the active compounds in
cells transfected only with the promiscuous G protein. However, as
several of the compounds including malonate, itaconate, and oxalo-
acetate are known to inhibit succinate dehydrogenase (SDH), which
could lead to accumulation of succinate and subsequent indirect
activation of GPR91, we further validated our ﬁndings in Ca2þ signaling
assays, which, in contrast to the IP3 assay, provide a very quick
response (i.e. withinw2 s). All compounds gave clear, rapid increases
in intracellular calcium (Figure S4), indicating that these compounds
most likely act directly as agonists on GPR91.
In agreement with a recent report from Geubelle and coworkers [29],
the main conclusion from the initial SAR analysis using succinate
analogs was that the cis conformation of the backbone is preferred and
that certain substitutions of the succinate backbone are allowed, thus
encouraging further search for non-metabolite GPR91 agonists.
3.2. GPR91 receptor modeling and molecular recognition of
succinate
From an evolutionary point of view, GPR91 is closely related to the
purinergic receptors (Figure 2A) and in particular P2Y1 for which a high
resolution X-ray structure was recently published [30]. Using a com-
bination of ICM (Molsoft L.L.C. 11199 Sorrento Valley Road, S209 San
Diego CA 92121) and the Rosetta modeling package, which sample
backbone and loop conformations by fragment assembly, we
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generated a three-dimensional hGPR91 homology model, using the
structure of hP2Y1 as a template. Based on molecular modeling and
mutagenesis, it was originally proposed that succinate in GPR91 would
bind between three arginine residues, Arg99 (ArgIII:05/3.29), Arg252
(ArgVI:20/6.55) and Arg281 (ArgVII:06/7.39) located in the pocket be-
tween the extracellular segments of TM-III, -VI and -VII [2]. Importantly
in P2Y1, the guanidino functions of ArgIII:05 and ArgVI:20, from each
side interact closely with Asp174, which points deep into the main
ligand binding pocket from ECL-2b, the backbone of which forms an
unusual loop buried in the pocket (Figure 2B). This complex is
apparently further stabilized by a number of interactions with other
highly conserved polar residues: His103 (HisIII:09), Tyr277 (TyrVII:02)
and Arg281 (ArgVII:06). All of the indicated residues are conserved in
GPR91 relative to the purinergic receptors and in the model of GPR91
these residues form a similar, apparently very stable complex ﬁlling the
deep part of the main ligand binding pocket. Based on this observation,
we reasoned that Arg99 (ArgIII:05) and Arg252 (ArgVI:20) are probably
not directly involved in succinate binding, despite the fact that we could
conﬁrm the original observation that mutational substitution of these
two residues severely impaired succinate activation of GPR91
(Table S1). Conceivably, these effects are indirect and likely related to
disruption of the special ‘plug’ structure of ECL-2b in part of the main
ligand binding pocket. Interestingly, the [R95L]mGPR91 receptor
construct displayed very high constitutive activity not observed in the
wildtype receptor (Figure 2D).
As the basis for in silico screening, the top scored GPR91 models were
expanded to another 21 models through elastic network modeling
using ICM v.3.8 (Molsoft L.L.C., San Diego, CA, USA) to broadly sample
the binding pocket geometry and the conformational variability of the
receptor. Against each of the 21 models, we computationally docked
succinate using an ensemble docking strategy called four-dimensional
docking (4D Dcoking) in ICM [25], which effectively consider all
structures in the ensemble in a single docking run. Investigation of the
top ranked binding conformations revealed that the central CH2-CH2 of
the succinate backbone functions as a spacer for optimal positioning of
the two terminal carboxylic acid moieties to make saltebridge in-
teractions with the originally proposed ‘third’ arginine residue, Arg281
(ArgVII:06) and a previously unnoticed Arg255 (ArgVI:23) located one
helical turn above Arg252 (ArgVI:20) in TM-VI and interestingly also
picking up interactions with the backbone -NH of Asp174 (Figure 2E).
The strongly impaired potency of succinate upon mutational substi-
tution of Arg255 (ArgVI:23) supported the notion that this is involved in
ligand binding (Figure 2D). The proposed binding conformation of
succinate is in agreement with the structure activity relationship of the
succinate analogs (Figure 1), i.e. in particular the activity of maleate vs.
fumarate indicating a preferred cis conformation of the backbone in the
binding pose (Figure 2E).
Thus, the P2Y1 receptor based molecular modeling and docking
identiﬁed what we believe is the real binding site for succinate in GPR91
and, importantly, the model of the succinate-GPR91 complex reveals
Figure 2: Molecular modeling of the GPR91-succinate complex. A) Comparison of the of P2Y1 X-ray structure (pdbid:4xnw, green) and the homology of the human and mouse
GPR91 receptors (gray) generated based on the P2Y1 structure with ECL-2b buried deep in between TM-III, -V and eVI highlighted in dark green. Side view from TM-IV and eV. B)
Detailed side view (with TM-IV and eV removed) of the interactions between ECL-2b e in particular Asp174 e and transmembrane residues in the P2Y1 receptor and the
corresponding interactions in the models of hGPR91 and mGPR91. C) ‘Pseudo-sequence’ of conserved network of polar and positively charged residues, which are found close to
Asp174 (ECL-2b) in the main ligand binding pocket of P2Y1, and h and mGPR91. Positions are annotated both with Ballesteros Weinstein and Schwartz numbering (used in most
ﬁgures). D) Dose-response curves for succinate in HEK-293 cells transfected with either the WT mGPR91 (dotted line) or the [R95L]mGPR91 (Arg:05/3.29) (left panel) proposed to
affect activity as shown in panel B or [R251L]mGPR91 (ArgVI:23/6.58) (right panel) which is proposed to affect activity directly through interaction with succinate binding panel E.
Red arrows indicate shifts in potency and efﬁcacy induced by mutations (N¼ 3). E) Extracellular view of the top-ranking binding conformation of succinate (yellow) in complex with
hGPR91. Note interaction of one caboxylate of succinate with the backbone -NH of Asp174 in ECL-2b and with ArgVII:06 (from the ‘bottom’ of the pocket) and the other carboxylate
with ArgVI:23. The unoccupied pocket extending towards TM-I and eII from the proposed binding site of succinate, which we in the following try to exploit for binding of synthetic
succinate analogs is indicated by a dotted circle.
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that a relatively large empty pocket extends towards TM-I and eII
from this binding site of succinate; i.e. a pocket which potentially
could be exploited by succinate analogs for binding (Figure 2E).
3.3. Identiﬁcation of non-metabolite GPR91 agonists
Computational screening of thew12 million compounds of the in-stock
subset of the ZINC database [31] was performed using a combination of
large scale substructure searches and molecular docking (see methods
for details). The search query was based on a Markush substructure
which included i) a carboxylic acid and/or acidic (bio)isosters corre-
sponding to one of the two carboxylates of succinate; ii) a one to three
atom linker to an acceptor and/or another carboxylic acid/acidic (bio)
isoster corresponding to the other COOH of succinate; and iii) up to three
R groups connected to the linker atoms, supported by the GPR91-
succinate models (Figure 3A). The positive hits were ﬁltered based on
drug-like properties and cluster analysis of 652 accepted compounds
revealed 139 cluster representatives using a Tc threshold of 0.3. A
small library of 111 compounds was selected and acquired based on
subjective investigator (TMF) inspection and assessment of chemical
complementary and key interactions of the GPR91-succinate model
(Table S2). The 111 compounds were tested for their ability to activate
GPR91 expressed in transfected HEK293 cells. Twenty compounds from
library #1 displayed potencies below 1 mM on the human and mouse
GPR91 and two compounds (compounds 48 and 104) were almost as
potent as succinate on the human receptor (Figure 3B). Dose-response
curves and structures for the three hits with the highest potency on
human GPR91 are shown in Figure 3C. Compound 48, 1,2-
cyclopropane-dicarboxylic acid, has recently been identiﬁed as a
GPR91 agonist among succinate analogs [29]. Molecular docking of
compound 104 demonstrated that the left hand-side succinate moiety
docked in a similar mode as succinate itself while the amide-linked
hydrophobic right hand-side docked into the extended side pocket
(Figure 3D). Due to the limited availability of extended analogs of
compound 48, we chose to focus on compounds 104 and 109, which
were used as seed structures for substructure and similarity-based
searches including structural knowledge of SAR and predicted bind-
ing conformations to acquire a second-generation library (library #2,
Table S3) containing 134 compounds. Only 12 compounds e most of
which were analogs of compound 104 e displayed potencies below
1 mM on both the human and mouse GPR91 receptor (Figure 4A). Non-
amide linked analogs of compound 104 were all negative, explaining
the relatively low hit rate in library #2. However, among the amide linked
Figure 3: Generation of initial succinate-based GPR91-targeted compound library. A) Schematic illustration of the multivariable Markush structure used for virtual screening
of the ZINC database containing >12 million biologically relevant compounds. B) Scatterplot of agonist potencies of the 111 compounds of library #1 tested by IP3 accumulation in
GPR91 transfected HEK-293 cells. C) Dose response curves and structures of the three most potent hits from library #1 on human GPR91: comp. 48, 104 and 109. D) Compound
104 (in green) docked into the molecular model of hGPR91 (gray). Yellow dashed line indicated proposed hydrogen bonds.
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analogs, eight compounds displayed up to 50-fold improved potency on
the human and up to 200-fold improved potency on the mouse GPR91
receptor (Figure 4A). Among these, compound 131 was highly selective
for the human receptor, compound 184 was highly selective for the
mouse receptor, and compound 130 displayed high potency for both
(EC50 on hGPR91 ¼ 1.9 mM and EC50 on mGPR91 ¼ 215 nM), with
compounds 130 and 131 both having more than 10-fold higher potency
than succinate on hGPR91 (Figure 4B). The structural basis for the
species selectivity of the compounds is likely related to one or more of
the six amino acid residues, which differ between the mouse and the
human receptor in the proximity to the ‘side-pocket’ where the amide-
linked hydrophobic moiety of these compounds bind (Table S1). All
three compounds appeared to be 60e80% partial agonists as
compared to succinate in the IP3 signaling assay.
As the positive synthetic non-metabolite compounds all have a stereo
center around the succinate backbone carbon where the amide linker
is attached, we synthesized the R and S form of each compound and
tested them for GPR91 activation. As observed for the metabolite
succinate analogs, the S-form of all three compounds was more potent
than the R-form; 21-fold for compound 130 and 6.4-fold for compound
184 (Figure 4C), and 6.7-fold for compound 131 (not shown). That the
differences between the two stereoisomers were not larger could be
related to the possibility for multiple different interaction modes of the
succinate moiety (see below).
The starting point of this study was that the novel synthetic GPR91
agonists should be selectively acting as receptor ligands and not as
intracellular metabolites. We therefore tested whether the compounds
affected succinate dehydrogenase (SDH) activity, which is the case for
Figure 4: Generation of second GPR91-targeted library based on compounds 109 and 104 from library #1 including stereochemical clariﬁcation and SDH activity of
the most potent compounds. A) Scatterplot of in vitro agonist potencies of library #1 (blue circles) and #2 (red circles) on the human and mouse GPR91 receptor, including
chemical structures of the most potent hits, as determined from IP3 accumulation assays in transfected HEK293 cells. B) Dose response curves of comp. 130, 131, and 184 on
mGPR91 (top) and hGPR91 (bottom) (N¼ 3) as compared to succinate (dotted line). C) The effect on IP3 turnover for the racemate of comp. 184 (left panel) and comp. 130 (right
panel) (black dotted lines) and the (S) and (R) enantiomers of each of these compounds as indicated, compared to succinate (gray dotted line). All compounds are tested on
mGPR91 (N¼ 3). D) Succinate dehydrogenase (SDH) activity during stimulation with comp. 130, 184, and 131 (100mM), and malonate (2 mM) included as a positive inhibitory
control (N¼2).
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a number of metabolite succinate analogs. As shown in Figure 4D, in
contrast to the positive control malonate, none of the GPR91 positive
synthetic compounds affected SDH activity.
3.4. Chemical novelty and selectivity of the non-metabolite GPR91
agonists
To assess the novelty of compounds 130, 131, and 184, we compared
their two dimensional structural similarities tow1.5 million annotated
chemicals in the ChEMBL20 database [32]. The similarity was quan-
tiﬁed by computed Tanimoto coefﬁcients (Tc) based on 2D ﬁngerprints
using Babel [26]. The highest Tc to compounds in ChEMBL was 0.75,
0.85, and 1.0 for compounds 130, 131, and 184, respectively. Since
the maximal Tc values of 1.0 is obtained for identical compounds,
whereas smaller values represent lower similarity, compounds 130
and 131 represent truly novel chemotypes as they are chemically
distinct from compounds previously reported to be active on other
protein targets (Table S4). Importantly, despite the fact that compound
184 has been used in general screens, it is not reported to possess
signiﬁcant activities on any targets [32].
We furthermore subjected compound 130 to a screen in both agonist
and antagonist mode on the 165 non-GPR91 GPCR receptors
(gpcrMAX) in the DiscoverX proﬁling service (https://www.discoverx.
com), and no signiﬁcant activity (all < 30%) on any of the targets
was observed (data not shown).
3.5. Docking and mutational analysis of non-metabolites versus
succinate in GPR91
Compounds 130 and 131 were probed in the human and compounds
130 and 184 in the murine GPR91 receptor (Table S1). As shown in
Figure 5A and E, both compound 131 and compound 184 docked
nicely into the main ligand binding pocket of the receptor with the
succinate moiety interacting with the central arginine residues and
with the amide-linked hydrophobic groups located in the extended side
pocket reaching over to TM-I and eII. Interestingly, the preferred
binding pose for the succinate moiety of the non-metabolite com-
pounds was slightly different from that of succinate itself. Although a
cis conformation of the backbone was preferred, and each of the two
carboxylic acid moieties interacted closely with ArgVII:06 and ArgVI:23,
no interaction with the backbone -NH group of Asp174 of ECL-2b was
observed in contrast to the unmodiﬁed succinate. Instead in both
compounds the carboxylate moiety next to the amide-linker apparently
picked up interactions with the guanidino function of ArgIII:05, which
was not observed with the unmodiﬁed succinate (Figure 2E vs.
Figure 5A and E). Importantly, a close H-bond interaction of the amide
linker with the guanidino moiety of ArgVII:06 was observed, which
would explain the strong dependency of the amide linker in analogs of
compound 104 in library #2 and the somewhat different pose of the
neighboring succinate moiety of these compounds as compared to the
unmodiﬁed succinate.
The mutational analysis demonstrated that the activity of all three
compounds was totally dependent upon ArgVII:06 as observed also for
the unmodiﬁed succinate (Figure 5B and F) and was also severely
impaired by substitution of ArgVI:23 similar to succinate (Figure 5G).
Among the effect of the other mutations in the binding pocket, the most
important and differentiating ones were those involving substitutions at
the extracellular ends of TM-I and II (Table S1). Thus, while the Phe-
substitution of the Lys residue just preceding TM-I (LysI:-01) slightly
improved the potency of both compounds 130 and 131 (Figure 5C),
Figure 5: Mutational mapping of novel synthetic non-metabolite GPR91 agonists exploiting the side-pocket to the succinate binding site in GPR91. A) Molecular model
of hGPR91 in complex with the human selective comp. 131 (green) with the succinate moiety binding with one carboxylate interacting with ArgVI:23 and the other carboxylate with
ArgIII:05 and ArgVII:06 which also binds the amide linker. To the right are highlighted the proposed edge to face aromatic interaction between the terminal aryl of comp. 131 and
the phenylalanine introduced in the gain-of-function mutation [K23F]hGPR91 (LysI:-01/1.32) (gray transparent spheres). Dose response curves for succinate (black) comp. 131
(green), and comp. 130 (blue) in selected mutant forms of human GPR91 are show in: B) [R281F]hGPR91 (ArgVII:06/7.39), C) [K23F]hGPR91 (LysI:-01/1.32), and D) [S82F]hGPR91
(SerII:23/2.63) in all panels compared to WT hGPR91 in dotted lines. Chemical structures of all compounds are shown at the top. E) Molecular model of mGPR91 in complex with
the murine selective comp. 184 (green) with the succinate moiety binding with one carboxylate interacting with ArgVI:23 and the other carboxylate with ArgIII:05 and ArgVII:06
which also binds the amide linker in a similar manner as comp. 131 in the human receptor (panel a). Dose response curves for succinate (black) comp. 184 (green), and comp. 130
(blue) in selected mutant forms of murine GPR91 are shown in: F) [R276F]mGPR91 (ArgVII:06/7.39), G) [R251L]mGPR91 (ArgVI:23/6.58), and H) [S78F]mGPR91 (SerII:23/2.63).
Chemical structures are shown at the top. Red arrows indicate shifts in potency and efﬁcacy induced by mutations.
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conceivably through establishing an aromaticearomatic interaction
with the terminal phenyl moiety of these compounds (Figure 5A), this
substitution had no effect on succinate. Most signiﬁcantly, Phe-
substitution of SerII:23 at the extracellular end of TM-II in mGPR91
strongly improved the potency of compound 184 (from
EC50¼ 267 nM to 6 nM) (Figure 5H) likely through establishment of an
edge-to-face aromaticearomatic interaction with the terminal aryl
group (Figure 5E). The similar SerII:23 to Phe substitution did not affect
compound 130 neither in mGPR91 nor in hGPR91, but it totally
eliminated the activity of compound 131 conceivably through steric
hindrance as compound 131 is longer than compound 130 (Figure 5D).
As expected, the [SerII:23Phe] substitution had no effect on succinate
in agreement with its presumed binding site far away from TM-II.
It is concluded that the synthetic succinate analogs bind in the main
ligand binding pocket of GPR91 with the succinate moiety mimicking
the binding mode of unmodiﬁed succinate with minor yet signiﬁcant
differences caused by the interaction of not only one of the carbox-
ylates, but importantly also the carbonyl of the amide linker as a main
anchor point interacting with ArgVII:06. The hydrophobic moieties of
these compounds dock into the extended side pocket to reach over to
residues at the extracellular end of TM-I and eII, which is substanti-
ated through both loss-of-function but also major gain-of-function
mutagenesis.
3.6. Comparing ex vivo effect of non-metabolite compounds with
succinate
Above we have only studied effects of the synthetic non-metabolite
compounds on a single signal transduction pathway and in trans-
fected HEK293 cells. In order to probe the effects of these compounds
on biological endpoints in cells endogenously expressing GPR91, we
turned to macrophages, which are known to express GPR91
[12,18,19]. However, as shown in Figure 6A, we ﬁnd that GPR91 is
particularly highly expressed in ‘alternatively activated’ macrophages
(often referred to as M2 macrophages) generated from primary cul-
tures of human monocytes by a combination of IL-4 and IL-13 as
opposed to ‘classically activated macrophages’ (often referred to as
M1 macrophages) i.e. stimulated by interferon-g (IFNg) and LPS.
Consequently, we studied the effects of compound 131 on cytokine
expression in primary cultures of human alternatively activated mac-
rophages and compared it with succinate. Both compound 131 and
succinate suppressed the expression of IL-10 and apparently
increased the expression of TNF-a in the alternatively activated
macrophages in a rather similar manner (Figure 6B). Compound 131
and succinate also suppressed the expression of toll like receptors
(TLR) 4 and 5 in a similar manner.
It is concluded that the novel synthetic non-metabolite GPR91 agonists
act as potent and efﬁcacious GPR91-dependent agonists affecting
human macrophage function in a similar manner as succinate, indi-
cating that these effects of succinate are mediated via GPR91 and not
via its effects as a classical metabolite.
4. DISCUSSION
In the present study, we describe the structure-based discovery of high
potency, synthetic, non-metabolite partial agonists for the succinate
receptor GPR91. The best compounds were backbone modiﬁed ana-
logs of succinate, in which an amide-linked hydrophobic moiety ﬁtted
into an extended side pocket next to the succinate binding site. The
compounds, which displayed similar GPR91 dependent activities in
human macrophages as succinate, for example, but did not affect the
major intracellular succinate target SDH, were discovered through
generation of GPR91-customized mini-libraries picked through virtual
screening of commercially available compounds.
4.1. Site-directed discovery of novel non-metabolite agonists for
GPR91
We originally developed this basic technology in the biotech industry to
obtain hits and leads in GPCR drug discovery [33]. Here we have
applied the technology in a modiﬁed form in an academic setting, and
successfully identiﬁed nanomolar agonists for GPR91 through the
generation of two mini libraries of less than 250 compounds in total e
while employing the synthesis of only a few novel compounds to solve
the stereochemistry of receptor recognition. Recently we have applied
the original site-directed approach to the Zn2þ sensor GPR39 by using
its endogenous ligand Zn2þ [34e36] as an essential allosteric
modulator to bring low-potency hits into the working range of the
biological assays [37]. In the case of GPR91, our initial SAR analysis
indicated that certain back-bone modiﬁcations of succinate were
allowed and that the cis conformation of the backbone was preferred.
Furthermore, our molecular modeling and computational chemistry
analysis demonstrated that an empty pocket was located next to the
succinate binding site. These observations were important for the
design of our multivariable substructure-based search query for the
virtual screening, which we believe was key to the success of the
approach and the limited size of the mini-libraries.
In the academic setting, the present cost-efﬁcient computational
approach complements “random” experimental testing of large
compound collections, e.g. High-Throughput Screening (HTS) which
currently is becoming available in a number of institutions [38]. A major
advantage of the computational approach is that it allows for bias in the
Figure 6: Effects of synthetic, non-metabolite GPR91 agonists and succinate on human macrophage gene expression. A) Expression of hGPR91 in human M1 and M2
macrophages determined by qPCR (N¼ 3). B) Effect of succinate (black columns) and compound 131 (dark blue columns) on the expression of IL-10, TNF-a, TLR4 and TLR5 in M2
macrophages determined by qPCR (N¼ 3). * P< 0.05, one-way ANOVA multiple comparisons test.
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search strategy toward speciﬁc aims, such as e.g. enhancing certain
physiochemical and/or pharmacological properties of particular novel
chemotypes, and importantly, requiring only limited chemical syn-
thesis. Application of other types of structure-based virtual screening
approaches, using the actual ligand-binding sites of high-resolution X-
ray structures of GPCR-ligand complexes, have proven to be similarly
efﬁcient in identifying novel ligands for these sites [39e44].
Recently the Roth and Shoichet groups have with great success
applied such docking approaches to opioid and opioid-like receptors.
Through computational docking of more than 3 106 compounds they
identiﬁed new scaffolds for the m-opioid receptor and eventually
identiﬁed a novel agonist with minimal activation of the arrestin
signaling pathway and associated respiratory depressive side effects
[45]. Similarly, for the atypical opioid receptor MRGPRX2, a novel
potent and selective agonist was identiﬁed through screening of 5.500
compounds and subsequent docking of nearly 4  106 compounds
into the receptor based on the initially identiﬁed hits [46]. Such studies,
together with the present study, illustrate the potential of applying
computational chemistry based technologies and receptor structures
or models for the identiﬁcation of novel pharmacological tool com-
pounds and potential drug leads in the academic setting.
4.2. Elucidation of the presumed binding site for succinate in
GPR91
Mutagenesis has for many years been used extensively for identiﬁ-
cation of ligand binding sites in GPCRs [47]. However, it is very difﬁcult
to differentiate between direct and indirect effects of mutations. In the
case of GPR91, it was originally proposed based on receptor muta-
genesis that succinate would bind between three arginine residues
located in what generally was considered to be the main ligand binding
pocket of GPCRs [2]. This binding site was recently ‘conﬁrmed’ by
another group [29]. However, our molecular modeling of GPR91 over
the recently published high resolution X-ray structure of the closely
related P2Y1 purinergic receptor revealed that two of the three origi-
nally identiﬁed arginine residues (ArgIII:05/3.29 and ArgVI:20/6.55),
which were believed to interact directly with succinate, are in fact both
bound up in interactions with an aspartate residue, Asp174, located in
an extracellular loop (ECL-2b), which makes an unusual loop down into
the main ligand binding pocket. These residues and the special loop of
ECL-2b are conserved among the purinergic receptors to which GPR91
structurally belongs [30]. This knowledge enabled us to identify what
we believe is the real binding site for succinate located between the
‘third’ originally identiﬁed ArgVII:06/7.39 and the previously unnoticed
ArgVI:23/6.58. This binding site was used as part of the basis for the
search query in the virtual screening of compounds (see above). We
believe that the deleterious effects of mutational substitutions of the
‘two other’ arginine residues, ArgIII:05 and ArgVI:20 [2,29], i.e. effects
which we could conﬁrm, are indirect and caused by major changes in
the structure of the whole binding pocket due to destabilization of the
complex which holds part of ECL-2b down in the pocket. Interestingly,
we observed that mutational substitution of ArgIII:05 in GPR91 resulted
in a very high constitutive signaling activity (Figure 2D). This indicates
that the ECL-2b ‘protein plug’ in GPR91 may function as a tethered
inverse agonist e i.e. a structural component which keeps the un-
occupied receptor silent, which may also be the case in the closely
related purinergic receptors. It should be noted that although many e
and even key e residues of the main ligand binding pocket are
conserved among the purinergic receptors and GPR91, the ‘previously
unnoticed’ ArgVI:23, which we ﬁnd is very important for binding and
activity of both succinate and the novel synthetic agonists, is not
conserved in the P2Y1 and in the P2Y12, where this position is
occupied by an asparagine and a tyrosine residue, respectively. This
may be the major reason why succinate does not work in these other
closely related receptors. Although the novel synthetic agonists
probably also obtain some of their selectivity through their interaction
with the GPR91-unique, ArgVI:23 these larger compounds in addition
interact with residues in the extended side-pocket, which also differs
between GPR91 and the purinergic receptors.
4.3. GPR91 as a potential drug target
GPR91 appears to be a highly interesting drug target due to its role as a
sensor of succinate accumulation, which occurs in multiple conditions
as an important part of the cellular response to metabolic stress and
hypoxia. The major molecular regulator of succinate concentrations,
SDH is an enzyme complex central not only to the TCA cycle but also
the electron transport chain (complex II). Thus, when succinate is
oxidized to fumarate, FAD is reduced and electrons are channeled to
ubiquinone through SDH [48]. Inhibition of SDH activity and the
associated accumulation of succinate is observed in response to
ischemia [11], hypoxia [49], and hyperglycemia [15], and the
accompanying GPR91-induced responses are linked with beneﬁcial
tissue adaptation to hypoxia/ischemia such as VEGF production in brain
and retina [13,50], cardiac hypertrophy [51], hepatic stellate cell
transdifferentiation [4], and renin release [9]. However, when the
succinate accumulation and GPR91 stimulation becomes more
chronic, as for example in response to hyperglycemia in diabetic pa-
tients [15], these effects become harmful. Importantly, GPR91 also
plays a central role in the massive inﬁltration of macrophages that is
driving the low grade inﬂammation associated with obesity [12].
However, although GPR91 in many ways appears to be an attractive
new drug target in relation to very difﬁcult indications, such as diabetic
retinopathy and nephropathy [15], very little is in fact still known about
the basic physiology and pharmacology of this receptor. The structural
simplicity of the ligand and the postulated tight binding pocket of
GPR91 have probably been discouraging factors for the pharmaceutical
exploration of this receptor. The new, highly selective GPR91 ligands,
which are devoid of succinate metabolite-like actions, represent great
tools to help clarify both the physiological function and the pharma-
cological potential of GPR91 as here exempliﬁed by the effects on
cytokine expression in the alternatively activated (M2) macrophages.
Recently, Geubelle and coworkers published a couple of small con-
formationally constrained succinate analogs cis-epoxysuccinic acid
(cESA) and cis-cyclopropane-1,2-dicarboxylic acid (cCPDA)
(Figure S5), the latter of which was also an initial hit in our study, as
being GPR91 full agonists with potencies similar to succinate itself but
devoid of SDH activity [29]. The best of the synthetic compounds
identiﬁed in the present study, compounds 130 and 131 display higher
potency but slightly less efﬁcacy. Importantly, as opposed to cESA and
cCPDA, the chemical series of GPR91 agonists presented here offers
straight forward medicinal chemistry possibilities for further optimi-
zation in respect of efﬁcacy and potency. These ligands could serve not
only as the basis for further development of GPR91 agonists with, for
example, differential signaling properties, but because many of them
are partial agonists, they may also serve as starting points for the
development of antagonists, which likely will be the preferred GPR91
drug, although this is still unclear due to the lack of useful pharma-
cological tools e until now. In 2011, a series of synthetic GPR91
antagonists were published [52]. Some of these antagonists were
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orally active and inhibited succinate induced hypertension; however,
further development of these have to our knowledge not been reported.
Succinate analogs like the ones described here or in a potential
antagonistic form will most likely have a relatively low bioavailability.
To circumvent this, we have synthesized a pro-drug of compound 130
converting the two carboxylates into esters. Preliminary data using this
pro-drug are very promising as high plasma concentrations of com-
pound 130 can be measured after oral administration in mice, indi-
cating that it should be possible to use compounds from this chemical
series to study effects of selective GPR91 activation also in the in vivo
setting after oral administration.
GPR91 is just one out of many receptors through which key metabolites
control endocrine and metabolic tissues and immune cell function, for
which the physiological in most cases still is poorly understood [1,53].
For some of these receptors, such as HCAR2 (GPR109a), many different
types of pharmacological tools are available because the receptor
previously has been probed as drug targets for ‘the wrong’ indications
[1]. However, for most of the metabolite receptors such compounds are
unfortunately not available. Through computationally based techniques
such as those described in the present study it is likely that useful,
synthetic non-metabolite ligands can be identiﬁed also for the other
metabolite receptors and for other interesting GPCRs in general.
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